Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.52 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 6/20 | 0.45 |
| ▸ | ACACA | Q13085 | 6/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12082491 | 0.86 | CKS1B (0.49) | SIRT2SIRT1SIRT3CKS1BSKP1 | |
| SCHEMBL30151471 | 0.84 | AKT2 (0.58) | SIRT2SIRT1SIRT3CKS1BSKP1 | |
| SCHEMBL4124235 | 0.84 | AKT2 (0.58) | SIRT2SIRT1SIRT3CKS1BSKP1 | |
| SCHEMBL1001746 | 0.84 | CNR1 (0.50) | SIRT2SIRT1SIRT3CKS1BSKP1 | |
| SCHEMBL24805277 | 0.83 | AKT1 (0.53) | SIRT2SIRT1SIRT3CKS1BSKP1 | |
| SCHEMBL14391712 | 0.82 | AKT2 (0.58) | SIRT2SIRT1SIRT3CKS1BSKP1 | |
| SCHEMBL4123744 | 0.82 | SIRT2 (0.50) | SIRT2SIRT1SIRT3CKS1BSKP1 | |
| SCHEMBL3491159 | 0.79 | SIRT2 (0.40) | SIRT2SIRT1SIRT3KITAKT2 | |
| SCHEMBL1031240 | 0.77 | KIT (0.58) | CKS1BSKP1SKP2KIT | |
| SCHEMBL30225432 | 0.77 | KIT (0.58) | CKS1BSKP1SKP2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | GRK3, CNKSR1, CSNK1G3 | SIRT2 1462/4885SIRT1 977/4885SIRT3 765/4885 |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | OXSR1, CDK1, CDK3 | SIRT2 2652/4885SIRT1 2107/4885SIRT3 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.